Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
NCT00003662
Completed
RATIONALE: Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy or radiation therapy. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation in treating patients who have hematologic cancer or other hematologic or metabolic diseases.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2011
Locations: Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina +1 locations
Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
Register for Updates
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
NCT00055653
Completed
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/03/2011
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
Register for Updates
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease
NCT00003913
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation plus combination chemotherapy in treating patients who have hematologic cancer or nonmalignant hematologic disease.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/31/2010
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Register for Updates
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
NCT00003187
Completed
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Eliminating the T cells from the donor cells before transplanting them may prevent this from happening. PURPOSE: Randomized phase II/III trial to compare the effectiveness of conventional bone marrow transplantation with T cell-deple... Read More
Gender:
ALL
Ages:
55 years and below
Trial Updated:
02/23/2010
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina +1 locations
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Register for Updates
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
NCT00002707
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/02/2010
Locations: Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina +3 locations
Conditions: Breast Cancer
Register for Updates
Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
NCT00016458
Completed
OBJECTIVES: I. Determine the toxicity of cyclophosphamide and rabbit anti-thymocyte globulin in patients with diffuse systemic sclerosis. II. Determine the efficacy of this regimen in terms of controlling disease in these patients.
Gender:
ALL
Ages:
64 years and below
Trial Updated:
09/02/2008
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Systemic Sclerosis
Register for Updates
Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
NCT00014755
Completed
OBJECTIVES: I. Determine the toxicity of total-body irradiation, anti-thymocyte globulin, and cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell (PBSC) transplantation in patients with multiple sclerosis. II. Determine the disease response of patients treated with this regimen. III. Determine the safety and efficacy of filgrastim (G-CSF) for PBSC mobilization in this patient population.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/23/2005
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Multiple Sclerosis
Register for Updates